Safety and efficacy of targeted agents monotherapy in advanced NSCLC
作者： Qi Zhang , Yi-Long Wu
DOI: 10.1586/17512433.2016.1101340
关键词:
摘要: The emergence of targetted therapy has revolutionised the treatment advanced NSCLC. Increasing numbers driver genes and related agents have supplied more powerful weapons for conquering Depending on whether there are clear targets therapeutic effects, we can now rank into three categories: with explicit pure theoretical but no effective biomarkers, vague lower effects. latest clinical data safety efficacy monotherapy kinds will be reviewed respectively in this article.
sci-hub.se 参考文章(110)
Peter Goldstraw, John J. Crowley, Ramon Rami-Porta, The revised TNM staging system for lung cancer. Annals of Thoracic and Cardiovascular Surgery. ,vol. 15, pp. 4- 9 ,(2009)
Julie R Brahmer, Leora Horn, Leena Gandhi, David R Spigel, Scott Joseph Antonia, Naiyer A Rizvi, John D Powderly, Rebecca Suk Heist, Richard D Carvajal, David Michael Jackman, Lecia V Sequist, David C Smith, Philip D Leming, Suzanne Louise Topalian, F Stephen Hodi, Mario Sznol, Christopher Harbison, Georgia Kollia, Ashok Kumar Gupta, Scott N Gettinger, None, Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. Journal of Clinical Oncology. ,vol. 32, pp. 8112- 8112 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.8112
Helena A. Yu, Gregory J. Riely, Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. Journal of The National Comprehensive Cancer Network. ,vol. 11, pp. 161- 169 ,(2013) , 10.6004/JNCCN.2013.0024
M. Catherine Pietanza, Thomas James Lynch, Primo N. Lara, John Cho, Ronald H. Yanagihara, Nandagopal Vrindavanam, Naveed Mahfooz Chowhan, Shirish M. Gadgeel, Nathan A. Pennell, Roel Funke, Ben Mitchell, Heather A. Wakelee, Vincent A. Miller, XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. Journal of Thoracic Oncology. ,vol. 7, pp. 219- 226 ,(2012) , 10.1097/JTO.0B013E31822EEBF9
Justin F. Gainor, Daniel S.W. Tan, Tomasso De Pas, Benjamin J. Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw, Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib Clinical Cancer Research. ,vol. 21, pp. 2745- 2752 ,(2015) , 10.1158/1078-0432.CCR-14-3009
Rebecca Sipples, Common Side Effects of Anti-EGFR Therapy: Acneform Rash Seminars in Oncology Nursing. ,vol. 22, pp. 28- 34 ,(2006) , 10.1016/J.SONCN.2006.01.013
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin J. Solomon, Juergen Wolf, Michael Thomas, Martin Schuler, Geoffrey Liu, Armando Santoro, Yvonne Y. Lau, Meredith Goldwasser, Anthony L. Boral, Jeffrey A. Engelman, Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 370, pp. 1189- 1197 ,(2014) , 10.1056/NEJMOA1311107
Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir, Christian Manegold, Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) Journal of Clinical Oncology. ,vol. 30, pp. 1114- 1121 ,(2012) , 10.1200/JCO.2011.36.1709
Craig Reynolds, Alexander I. Spira, Larry Gluck, Suzanne E. Mueller, Feng Zhan, Kristi A. Boehm, Lina Asmar, Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial. Investigational New Drugs. ,vol. 31, pp. 1330- 1338 ,(2013) , 10.1007/S10637-013-9985-0
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn, Enric Carcereny, Myung-Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D Hellmann, Omid Hamid, Jonathan W Goldman, Jean-Charles Soria, Marisa Dolled-Filhart, Ruth Z Rutledge, Jin Zhang, Jared K Lunceford, Reshma Rangwala, Gregory M Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi, None, Pembrolizumab for the treatment of non-small cell lung cancer The New England Journal of Medicine. ,vol. 372, pp. 2018- 2028 ,(2015) , 10.1056/NEJMOA1501824